An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
08 03 2023
Historique:
received: 08 09 2022
accepted: 23 01 2023
pubmed: 27 1 2023
medline: 10 3 2023
entrez: 26 1 2023
Statut: epublish

Résumé

As the COVID-19 pandemic continues, long-term immunity against SARS-CoV-2 will be important globally. Official weekly cases have not dropped below 2 million since September of 2020, and continued emergence of novel variants has created a moving target for our immune systems and public health alike. The temporal aspects of COVID-19 immunity, particularly from repeated vaccination and infection, are less well understood than short-term vaccine efficacy. In this study, we explored the effect of combined vaccination and infection, also known as hybrid immunity, and the timing thereof on the quality and quantity of antibodies elicited in a cohort of 96 health care workers. We found robust neutralizing antibody responses among those with hybrid immunity; these hybrid immune responses neutralized all variants, including BA.2. Neutralizing titers were significantly improved for those with longer vaccine-infection intervals of up to 400 days compared with those with shorter intervals. These results indicate that anti-SARS-CoV-2 antibody responses undergo continual maturation following primary exposure by either vaccination or infection for at least 400 days after last antigen exposure. We show that neutralizing antibody responses improved upon secondary boosting, with greater potency seen after extended intervals. Our findings may also extend to booster vaccine doses, a critical consideration in future vaccine campaign strategies.

Identifiants

pubmed: 36701200
pii: 165265
doi: 10.1172/jci.insight.165265
pmc: PMC10077480
doi:
pii:

Substances chimiques

Antibodies, Neutralizing 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL083808
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141549
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145835
Pays : United States

Commentaires et corrections

Type : UpdateOf

Références

N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
JAMA. 2022 Jan 18;327(3):279-281
pubmed: 34860253
Sci Immunol. 2022 Feb 18;7(68):eabn8014
pubmed: 35076258
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862
pubmed: 30356267
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263
pubmed: 35176007
Nat Commun. 2021 Aug 26;12(1):5135
pubmed: 34446720
Sci Immunol. 2021 Feb 23;6(56):
pubmed: 33622975
JAMA. 2022 Jan 11;327(2):179-181
pubmed: 34914825
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1306-1311
pubmed: 34529645
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
Nature. 2022 Apr;604(7904):141-145
pubmed: 35168246
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Nat Med. 2022 Apr;28(4):831-837
pubmed: 35045566
PLoS One. 2022 Apr 29;17(4):e0266958
pubmed: 35486622
Sci Immunol. 2021 Dec 03;6(66):eabi8635
pubmed: 34648369
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Nat Immunol. 2022 Mar;23(3):380-385
pubmed: 35115679
Environ Res. 2022 Jun;209:112911
pubmed: 35149106
Clin Infect Dis. 2023 Feb 8;76(3):e439-e449
pubmed: 35608504
Lancet Infect Dis. 2022 Apr;22(4):445-446
pubmed: 35240040
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
J Infect Dis. 2022 Mar 15;225(6):947-956
pubmed: 34865053
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Immunity. 2022 Oct 11;55(10):1856-1871.e6
pubmed: 35987201
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
Nat Med. 2021 Nov;27(11):2025-2031
pubmed: 34526698
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Nat Med. 2022 Jul;28(7):1461-1467
pubmed: 35614233
Science. 2022 Jan 21;375(6578):331-336
pubmed: 34735261
N Engl J Med. 2022 Mar 3;386(9):894-896
pubmed: 35081296
JAMA. 2021 Jul 21;:
pubmed: 34287620
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
N Engl J Med. 2022 Apr 28;386(17):1603-1614
pubmed: 35417631
Med. 2022 Apr 8;3(4):249-261.e4
pubmed: 35261995
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962
Lancet. 2022 Jun 25;399(10344):2351-2380
pubmed: 35405084
N Engl J Med. 2022 Jun 9;386(23):2201-2212
pubmed: 35613036

Auteurs

Timothy A Bates (TA)

Department of Molecular Microbiology and Immunology.

Hans C Leier (HC)

Department of Molecular Microbiology and Immunology.

Savannah K McBride (SK)

Department of Molecular Microbiology and Immunology.

Devin Schoen (D)

Division of Infectious Diseases, and.

Zoe L Lyski (ZL)

Department of Molecular Microbiology and Immunology.

David X Lee (DX)

Department of Molecular Microbiology and Immunology.

William B Messer (WB)

Department of Molecular Microbiology and Immunology.
Division of Infectious Diseases, and.
OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, Oregon, USA.

Marcel E Curlin (ME)

Division of Infectious Diseases, and.

Fikadu G Tafesse (FG)

Department of Molecular Microbiology and Immunology.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH